Quantum Biopharma (QNTM) said Tuesday it entered into a joint clinical study with the Massachusetts General Hospital to investigate an imaging technique to monitor demyelination in people suffering from multiple sclerosis.
The parties aims to validate a novel positron emission tomography, or PET, biomarker to monitor myelin integrity and measure demyelination. Multiple sclerosis is a chronic disease of the central nervous system.
The financial terms of the collaboration weren't disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.